An oral formulation of angiotensin-(1-7) reverses corpus cavernosum damages induced by hypercholesterolemia.

INTRODUCTION The renin angiotensin system plays a crucial role in erectile function. It has been shown that elevated angiotensin-II levels contribute to the development of erectile dysfunction (ED). Oppositely, angiotensin-(1-7) (Ang-[1-7]) mediates penile erection by activation of receptor Mas. Recently, we have developed a formulation based on Ang-(1-7) inclusion in cyclodextrin (CyD) [Ang-(1-7)-CyD], which allows for the oral administration of Ang-(1-7). AIM In the present study, we evaluated the effects of chronic treatment with Ang-(1-7)-CyD on penile fibrosis, oxidative stress, and endothelial function in hypercholesterolemic mice. METHODS Apolipoprotein(Apo)E-/- mice fed a Western-type diet for 11 weeks received Ang-(1-7)-CyD or vehicle during the final 3 weeks. Collagen content and reactive oxygen species (ROS) production within the corpus cavernosum were evaluated by Sirius red and dihydroethidium staining, respectively. Protein expression of neuronal nitric oxide synthase (nNOS) and endothelial nitric oxide synthase (eNOS), nicotinamide adenine dinucleotide phosphate (NADPH) subunits (p67-phox and p22-phox), and AT1 and Mas receptors in the penis was assessed by Western blotting. Nitric oxide (NO) production was measured by Griess assay in the mice serum. Cavernosal strips were mounted in an isometric organ bath to evaluate the endothelial function. MAIN OUTCOME MEASURES The effect of Ang-(1-7)-CyD treatment on penile fibrosis, oxidative stress, and endothelial function in hypercholesterolemia-induced ED. RESULTS Ang-(1-7)-CyD treatment reduced collagen content in the corpus cavernosum of ApoE-/- mice. This effect was associated with an attenuation of ROS production and a diminished expression of NADPH. Furthermore, Ang-(1-7)-CyD treatment augmented the expression of nNOS and eNOS in the penis and elevated vascular NO production. Importantly, these effects were accompanied by an improvement in cavernosal endothelial function. CONCLUSION Long-term treatment with Ang-(1-7)-CyD reduces penile fibrosis associated with attenuation of oxidative stress. Additionally, cavernosal endothelial function in hypercholesterolemic mice was markedly improved. These results suggest that Ang-(1-7)-CyD might have significant therapeutic benefits for the treatment of erectile dysfunction.

[1]  A. Burnett,et al.  Targeting NADPH oxidase decreases oxidative stress in the transgenic sickle cell mouse penis. , 2012, The journal of sexual medicine.

[2]  A. Ferreira,et al.  Beneficial Effects of Long-Term Administration of an Oral Formulation of Angiotensin-(1–7) in Infarcted Rats , 2012, International journal of hypertension.

[3]  P. Gallagher,et al.  Angiotensin-(1-7) attenuates angiotensin II-induced cardiac remodeling associated with upregulation of dual-specificity phosphatase 1. , 2012, American journal of physiology. Heart and circulatory physiology.

[4]  M. Raizada,et al.  New Cardiovascular and Pulmonary Therapeutic Strategies Based on the Angiotensin-Converting Enzyme 2/Angiotensin-(1–7)/Mas Receptor Axis , 2012, International journal of hypertension.

[5]  G. Brock,et al.  Investigative models in erectile dysfunction: a state-of-the-art review of current animal models. , 2011, The journal of sexual medicine.

[6]  R. Webb,et al.  Increased cavernosal relaxation by Phoneutria nigriventer toxin, PnTx2-6, via activation at NO/cGMP signaling , 2011, International Journal of Impotence Research.

[7]  S. Suresh,et al.  Effect of Mucuna pruriens (Linn.) on oxidative stress-induced structural alteration of corpus cavernosum in streptozotocin-induced diabetic rat. , 2011, The journal of sexual medicine.

[8]  M. Böhm,et al.  Telmisartan, ramipril and their combination improve endothelial function in different tissues in a murine model of cholesterol‐induced atherosclerosis , 2011, British journal of pharmacology.

[9]  N. Alenina,et al.  An orally active formulation of angiotensin-(1-7) produces an antithrombotic effect , 2011, Clinics.

[10]  A. Ferreira,et al.  An Oral Formulation of Angiotensin-(1-7) Produces Cardioprotective Effects in Infarcted and Isoproterenol-Treated Rats , 2011, Hypertension.

[11]  M. Raizada,et al.  Angiotensin‐converting enzyme 2 activation protects against hypertension‐induced cardiac fibrosis involving extracellular signal‐regulated kinases , 2011, Experimental physiology.

[12]  N. Alenina,et al.  ACE2–angiotensin-(1–7)–Mas axis and oxidative stress in cardiovascular disease , 2011, Hypertension Research.

[13]  Jun Ren,et al.  Angiotensin-(1-7) ameliorates myocardial remodeling and interstitial fibrosis in spontaneous hypertension: role of MMPs/TIMPs. , 2010, Toxicology letters.

[14]  M. Raizada,et al.  The angiotensin-converting enzyme 2/angiogenesis-(1-7)/Mas axis confers cardiopulmonary protection against lung fibrosis and pulmonary hypertension. , 2010, American journal of respiratory and critical care medicine.

[15]  A. Burnett,et al.  Hypercholesterolemia-induced erectile dysfunction: endothelial nitric oxide synthase (eNOS) uncoupling in the mouse penis by NAD(P)H oxidase. , 2010, The journal of sexual medicine.

[16]  W. Border,et al.  Infusion of angiotensin-(1-7) reduces glomerulosclerosis through counteracting angiotensin II in experimental glomerulonephritis. , 2010, American journal of physiology. Renal physiology.

[17]  M. Raizada,et al.  Therapeutic implications of the vasoprotective axis of the renin-angiotensin system in cardiovascular diseases. , 2010, Hypertension.

[18]  K. Sharma,et al.  Mechanisms of kidney fibrosis and the role of antifibrotic therapies , 2009, Current opinion in nephrology and hypertension.

[19]  U. Laufs,et al.  Improvement of Endothelial Function of the Corpus Cavernosum in Apolipoprotein E Knockout Mice Treated with Irbesartan , 2008, Journal of Pharmacology and Experimental Therapeutics.

[20]  M. Raizada,et al.  Angiotensin-(1-7) as an antihypertensive, antifibrotic target , 2008, Current hypertension reports.

[21]  D. Ganten,et al.  Update on tissue renin–angiotensin systems , 2008, Journal of Molecular Medicine.

[22]  F. Luft,et al.  Endothelial Dysfunction and Elevated Blood Pressure in Mas Gene-Deleted Mice , 2008, Hypertension.

[23]  H. A. Duarte,et al.  Study of angiotensin-(1–7) vasoactive peptide and its β-cyclodextrin inclusion complexes: Complete sequence-specific NMR assignments and structural studies , 2007, Peptides.

[24]  R. Touyz,et al.  Evidence that the vasodilator angiotensin-(1-7)-Mas axis plays an important role in erectile function. , 2007, American journal of physiology. Heart and circulatory physiology.

[25]  I. Benter,et al.  Different responses to angiotensin-(1-7) in young, aged and diabetic rabbit corpus cavernosum. , 2007, Pharmacological research.

[26]  B. Annex,et al.  A mouse model of hypercholesterolemia-induced erectile dysfunction. , 2007, The journal of sexual medicine.

[27]  M. Teixeira,et al.  The renin-angiotensin system in a rat model of hepatic fibrosis: evidence for a protective role of Angiotensin-(1-7). , 2007, Journal of hepatology.

[28]  J. Grobe,et al.  Chronic angiotensin-(1-7) prevents cardiac fibrosis in DOCA-salt model of hypertension. , 2006, American journal of physiology. Heart and circulatory physiology.

[29]  T. Lue,et al.  Physiology of penile erection and pathophysiology of erectile dysfunction. , 2005, The Urologic clinics of North America.

[30]  R. A. Santos,et al.  Cardiovascular actions of angiotensin-(1-7). , 2005, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[31]  K. Uekama,et al.  Design and evaluation of cyclodextrin-based drug formulation. , 2004, Chemical & pharmaceutical bulletin.

[32]  R. Touyz Reactive oxygen species and angiotensin II signaling in vascular cells -- implications in cardiovascular disease. , 2004, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[33]  W. Hellstrom,et al.  Endothelial dysfunction in erectile dysfunction: role of the endothelium in erectile physiology and disease. , 2003, Journal of andrology.

[34]  U. Jonas,et al.  Plasma levels of angiotensin II during different penile conditions in the cavernous and systemic blood of healthy men and patients with erectile dysfunction. , 2001, Urology.

[35]  Ç. Yeşilli,et al.  Effect of experimental hypercholesterolemia on cavernosal structures. , 2001, Urology.

[36]  A. Nishiyama,et al.  Systemic and Regional Hemodynamic Responses to Tempol in Angiotensin II–Infused Hypertensive Rats , 2001, Hypertension.

[37]  D. Ganten,et al.  Converting enzyme determines plasma clearance of angiotensin-(1-7). , 1998, Hypertension.

[38]  D. Udelson,et al.  Cavernosal expandability is an erectile tissue mechanical property which predicts trabecular histology in an animal model of vasculogenic erectile dysfunction. , 1998, The Journal of urology.

[39]  K. Cho,et al.  Renin angiotensin system in rabbit corpus cavernosum: functional characterization of angiotensin II receptors. , 1997, The Journal of urology.

[40]  R. Dluhy,et al.  Tissue angiotensin II as a modulator of erectile function. I. Angiotensin peptide content, secretion and effects in the corpus cavernosum. , 1997, The Journal of urology.

[41]  S. Snyder,et al.  Nitric oxide: a physiologic mediator of penile erection. , 1992, Science.

[42]  K. Azadzoi,et al.  Hypercholesterolemia impairs endothelium-dependent relaxation of rabbit corpus cavernosum smooth muscle. , 1991, The Journal of urology.

[43]  S. Wilson,et al.  Role of oxygen-derived free radicals in acute angiotensin II--induced hypertensive vascular disease in the rat. , 1990, Circulation research.

[44]  K. Baek,et al.  Involvement of superoxide radical in the impaired endothelium-dependent relaxation of cavernous smooth muscle in hypercholesterolemic rabbits , 2004, Urological Research.

[45]  U. Jonas,et al.  Possible role of bradykinin and angiotensin II in the regulation of penile erection and detumescence. , 2001, Urology.

[46]  M. Davies,et al.  Experimental hypercholesterolemia in rabbits induces cavernosal atherosclerosis with endothelial and smooth muscle cell dysfunction. , 1994, The Journal of urology.